| Literature DB >> 18424188 |
Marco Prinz1, Hauke Schmidt, Alexander Mildner, Klaus-Peter Knobeloch, Uwe-Karsten Hanisch, Jenni Raasch, Doron Merkler, Claudia Detje, Ilona Gutcher, Jörg Mages, Roland Lang, Roland Martin, Ralf Gold, Burkhard Becher, Wolfgang Brück, Ulrich Kalinke.
Abstract
The action of type I interferons in the central nervous system (CNS) during autoimmunity is largely unknown. Here, we demonstrate elevated interferon beta concentrations in the CNS, but not blood, of mice with experimental autoimmune encephalomyelitis (EAE), a model for CNS autoimmunity. Furthermore, mice devoid of the broadly expressed type I IFN receptor (IFNAR) developed exacerbated clinical disease accompanied by a markedly higher inflammation, demyelination, and lethality without shifting the T helper 17 (Th17) or Th1 cell immune response. Whereas adoptive transfer of encephalitogenic T cells led to enhanced disease in Ifnar1(-/-) mice, newly created conditional mice with B or T lymphocyte-specific IFNAR ablation showed normal EAE. The engagement of IFNAR on neuroectodermal CNS cells had no protective effect. In contrast, absence of IFNAR on myeloid cells led to severe disease with an enhanced effector phase and increased lethality, indicating a distinct protective function of type I IFNs during autoimmune inflammation of the CNS.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18424188 DOI: 10.1016/j.immuni.2008.03.011
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745